974 related articles for article (PubMed ID: 22214754)
21. Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study.
Akl EA; Kahale LA; Agarwal A; Al-Matari N; Ebrahim S; Alexander PE; Briel M; Brignardello-Petersen R; Busse JW; Diab B; Iorio A; Kwong J; Li L; Lopes LC; Mustafa R; Neumann I; Tikkinen KA; Vandvik PO; Zhang Y; Alonso-Coello P; Guyatt G
Syst Rev; 2014 Nov; 3():137. PubMed ID: 25423894
[TBL] [Abstract][Full Text] [Related]
22. Value and usability of unpublished data sources for systematic reviews and network meta-analyses.
Halfpenny NJ; Quigley JM; Thompson JC; Scott DA
Evid Based Med; 2016 Dec; 21(6):208-213. PubMed ID: 27686328
[TBL] [Abstract][Full Text] [Related]
23. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews.
McDonagh MS; Peterson K; Balshem H; Helfand M
J Clin Epidemiol; 2013 Oct; 66(10):1071-81. PubMed ID: 23856190
[TBL] [Abstract][Full Text] [Related]
24. Publication Bias and Nonreporting Found in Majority of Systematic Reviews and Meta-analyses in Anesthesiology Journals.
Hedin RJ; Umberham BA; Detweiler BN; Kollmorgen L; Vassar M
Anesth Analg; 2016 Oct; 123(4):1018-25. PubMed ID: 27537925
[TBL] [Abstract][Full Text] [Related]
25. FDA and CPMP rulings on subgroup analyses.
Maggioni AP; Darne B; Atar D; Abadie E; Pitt B; Zannad F;
Cardiology; 2007; 107(2):97-102. PubMed ID: 16847375
[TBL] [Abstract][Full Text] [Related]
26. Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies.
Windsor B; Popovich I; Jordan V; Showell M; Shea B; Farquhar C
Hum Reprod; 2012 Dec; 27(12):3460-6. PubMed ID: 23034152
[TBL] [Abstract][Full Text] [Related]
27. Reporting 'number needed to treat' in meta-analyses: a cross-sectional study.
Naing C; Aung K; Mak JW
J Evid Based Med; 2012 Nov; 5(4):232-7. PubMed ID: 23557504
[TBL] [Abstract][Full Text] [Related]
28. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
29. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.
Golder S; Loke YK; Wright K; Norman G
PLoS Med; 2016 Sep; 13(9):e1002127. PubMed ID: 27649528
[TBL] [Abstract][Full Text] [Related]
30. Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
Wang L; Rouse B; Marks-Anglin A; Duan R; Shi Q; Quach K; Chen Y; Cameron C; Schmid CH; Li T
J Clin Epidemiol; 2019 Oct; 114():84-94. PubMed ID: 31226413
[TBL] [Abstract][Full Text] [Related]
31. Association Between Publication Characteristics and Treatment Effect Estimates: A Meta-epidemiologic Study.
Dechartres A; Atal I; Riveros C; Meerpohl J; Ravaud P
Ann Intern Med; 2018 Sep; 169(6):385-393. PubMed ID: 30140933
[TBL] [Abstract][Full Text] [Related]
32. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
33. Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research.
Schmucker CM; Blümle A; Schell LK; Schwarzer G; Oeller P; Cabrera L; von Elm E; Briel M; Meerpohl JJ;
PLoS One; 2017; 12(4):e0176210. PubMed ID: 28441452
[TBL] [Abstract][Full Text] [Related]
34. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls.
da Costa BR; Juni P
Eur Heart J; 2014 Dec; 35(47):3336-45. PubMed ID: 25416325
[TBL] [Abstract][Full Text] [Related]
35. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.
Biondi-Zoccai GG; Lotrionte M; Abbate A; Testa L; Remigi E; Burzotta F; Valgimigli M; Romagnoli E; Crea F; Agostoni P
BMJ; 2006 Jan; 332(7535):202-9. PubMed ID: 16415336
[TBL] [Abstract][Full Text] [Related]
36. Data sources on drug safety evaluation: a review of recent published meta-analyses.
Alves C; Batel-Marques F; Macedo AF
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):21-33. PubMed ID: 22025370
[TBL] [Abstract][Full Text] [Related]
37. How useful are unpublished data from the Food and Drug Administration in meta-analysis?
MacLean CH; Morton SC; Ofman JJ; Roth EA; Shekelle PG;
J Clin Epidemiol; 2003 Jan; 56(1):44-51. PubMed ID: 12589869
[TBL] [Abstract][Full Text] [Related]
38. A protocol for a systematic review on the impact of unpublished studies and studies published in the gray literature in meta-analyses.
Schmucker C; Bluemle A; Briel M; Portalupi S; Lang B; Motschall E; Schwarzer G; Bassler D; Mueller KF; von Elm E; Meerpohl JJ;
Syst Rev; 2013 May; 2():24. PubMed ID: 23634657
[TBL] [Abstract][Full Text] [Related]
39. Survey of systematic reviews and meta-analyses published in ophthalmology.
Chen H; Jhanji V
Br J Ophthalmol; 2012 Jun; 96(6):896-9. PubMed ID: 22446144
[TBL] [Abstract][Full Text] [Related]
40. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
